Antonio Baici

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3822441/publications.pdf

Version: 2024-02-01

85

all docs

117625 161849 3,173 81 34 citations h-index papers

85

g-index 85 3050 docs citations times ranked citing authors

54

#	Article	IF	CITATIONS
1	Kinetics of Folding of Leucine Zipper Domains. Biochemistry, 1995, 34, 4097-4107.	2.5	170
2	Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases. FEBS Letters, 1999, 455, 286-290.	2.8	147
3	Inhibition of Caspase-2 by a Designed Ankyrin Repeat Protein: Specificity, Structure, and Inhibition Mechanism. Structure, 2007, 15, 625-636.	3.3	125
4	The Axonally Secreted Serine Proteinase Inhibitor, Neuroserpin, Inhibits Plasminogen Activators and Plasmin but Not Thrombin. Journal of Biological Chemistry, 1998, 273, 2312-2321.	3.4	121
5	The power stroke of the DnaK/DnaJ/GrpE molecular chaperone system 1 1Edited by J.Karn. Journal of Molecular Biology, 1997, 269, 757-768.	4.2	117
6	Antileukoprotease Inhibits Stratum Corneum Chymotryptic Enzyme. Journal of Biological Chemistry, 1996, 271, 21886-21890.	3.4	97
7	Very Rapid, Ionic Strength-Dependent Association and Folding of a Heterodimeric Leucine Zipper. Biochemistry, 1997, 36, 204-213.	2.5	94
8	Interaction of site specific hirudin variants with α-thrombin. FEBS Letters, 1988, 229, 87-90.	2.8	91
9	The Slow, Tight-Binding Inhibition of Cathepsin B by Leupeptin. A Hysteretic Effect. FEBS Journal, 1982, 129, 33-41.	0.2	90
10	Specific cleavage of agrin by neurotrypsin, a synaptic protease linked to mental retardation. FASEB Journal, 2007, 21, 3468-3478.	0.5	89
11	Inhibition of human elastase from polymorphonuclear leucocytes by a glycosaminoglycan polysulfate (Arteparon®). Biochemical Pharmacology, 1980, 29, 1723-1727.	4.4	88
12	Specific Inhibition of \hat{l}^2 -Secretase Processing of the Alzheimer Disease Amyloid Precursor Protein. Cell Reports, 2016, 14, 2127-2141.	6.4	87
13	Interaction between Human Cathepsins K, L, and S and Elastins. Journal of Biological Chemistry, 2007, 282, 7893-7902.	3.4	84
14	A novel allosteric mechanism in the cysteine peptidase cathepsin K discovered by computational methods. Nature Communications, 2014, 5, 3287.	12.8	77
15	The Specific Velocity Plot. A Graphical Method for Determining Inhibition Parameters for Both Linear and Hyperbolic Enzyme Inhibitors. FEBS Journal, 1981, 119, 9-14.	0.2	70
16	Interaction between human leukocyte elastase and chondroitin sulfate. Chemico-Biological Interactions, 1984, 51, 1-11.	4.0	68
17	Conformational flexibility and allosteric regulation of cathepsin K. Biochemical Journal, 2010, 429, 379-389.	3.7	65
18	Inhibition of human elastase from polymorphonuclear leucocytes by gold sodium thiomalate and pentosan polysulfate (SP-54 \hat{A}°). Biochemical Pharmacology, 1981, 30, 703-708.	4.4	59

#	Article	IF	CITATION
19	Relation between fluorescence and conformation of il̂µNAD+ bound to dehydrogenases. Biochemistry, 1975, 14, 362-368.	2.5	58
20	Exon Skipping of Cathepsin B. Journal of Biological Chemistry, 2004, 279, 41012-41017.	3.4	58
21	Monomeric and Dimeric bZIP Transcription Factor GCN4 Bind at the Same Rate to Their Target DNA Siteâ€. Biochemistry, 2004, 43, 718-727.	2.5	48
22	Mechanism of assembly of a leucine zipper domain. Journal of the American Chemical Society, 1994, 116, 6973-6974.	13.7	47
23	Alternative messenger RNA splicing and enzyme forms of cathepsin B in human osteoarthritic cartilage and cultured chondrocytes. Arthritis and Rheumatism, 2001, 44, 1819-1831.	6.7	46
24	Inhibition of the human leukocyte endopeptidases elastase and cathepsin G and of porcine pancreatic elastase by N-oleoyl derivatives of heparin. Biochemical Pharmacology, 1993, 46, 1545-1549.	4.4	42
25	Characterization of Human Matrilin-3 (MATN3). Genomics, 1998, 53, 391-394.	2.9	41
26	Kinetics and Mechanism of Long-Chain Fatty Acid Transport into Phosphatidylcholine Vesicles from Various Donor Systems. Biochemistry, 2002, 41, 1591-1601.	2.5	41
27	Production of agglutinators and rheumatoid factors in plasma cells of rheumatoid and nonrheumatoid synovial tissues. Arthritis and Rheumatism, 1981, 24, 510-519.	6.7	40
28	The alternative use of exonsÂ2 and 3 in cathepsinÂB mRNA controls enzyme trafficking and triggers nuclear fragmentation in human cells. Histochemistry and Cell Biology, 2003, 119, 93-101.	1.7	38
29	STRENDA DB: enabling the validation and sharing of enzyme kinetics data. FEBS Journal, 2018, 285, 2193-2204.	4.7	38
30	Influence of Ligands on the Coenzyme Dissociation Constants in Octopine Dehydrogenase. FEBS Journal, 1974, 46, 59-66.	0.2	36
31	A handy assay for collagenase using reconstituted fluorescein-labeled collagen fibrils. Analytical Biochemistry, 1980, 108, 230-232.	2.4	36
32	A doubleâ€headed cathepsin B inhibitor devoid of warhead. Protein Science, 2008, 17, 2145-2155.	7.6	36
33	Temperature-Determined Enzymatic Functions in Octopine Dehydrogenase. FEBS Journal, 1975, 50, 511-516.	0.2	35
34	Cathepsin B secretion by rabbit articular chondrocytes: modulation by cycloheximide and glycosaminoglycans. Cell and Tissue Research, 1990, 259, 567-573.	2.9	35
35	Regulation of human cathepsin B by alternative mRNA splicing: homeostasis, fatal errors and cell death. Biological Chemistry, 2006, 387, 1017-21.	2.5	35
36	Human caspases in vitro: Expression, purification and kinetic characterization. Protein Expression and Purification, 2012, 84, 236-246.	1.3	32

#	Article	IF	CITATIONS
37	Cathepsin B expression and down-regulation by gene silencing and antisense DNA in human chondrocytes. Biochemical Journal, 2002, 367, 209-217.	3.7	31
38	Dual concentration-dependent activity of thyroglobulin type-1 domain of testican: specific inhibitor and substrate of cathepsin L. Biological Chemistry, 2005, 386, 75-83.	2.5	29
39	Exploring the Role of 5' Alternative Splicing and of the 3'-Untranslated Region of Cathepsin B mRNA. Biological Chemistry, 2003, 384, 1007-18.	2.5	28
40	Cytoskeletal architecture and cathepsinÂB trafficking in human articular chondrocytes. Histochemistry and Cell Biology, 2000, 114, 363-372.	1.7	27
41	Cathepsin B in Osteoarthritis: Uncontrolled Proteolysis in the Wrong Place. Seminars in Arthritis and Rheumatism, 2004, 34, 24-28.	3.4	27
42	3â€Fluoroâ€2,4â€dioxaâ€3â€phosphadecalins as Inhibitors of Acetylcholinesterase. A Reappraisal of Kinetic Mechanisms and Diagnostic Methods. Chemistry and Biodiversity, 2009, 6, 261-282.	2.1	26
43	Cathepsin G from human polymorphonuclear leukocytes cleaves human IgM. Molecular Immunology, 1982, 19, 719-727.	2.2	25
44	The kinetic mechanism of inhibition of human leukocyte elastase by MR889, a new cyclic thiolic compound. Biochemical Pharmacology, 1990, 39, 919-924.	4.4	25
45	Effect of interleukin- $\hat{1}^2$ on the production of cathepsin B by rabbit articular chondrocytes. FEBS Letters, 1990, 277, 93-96.	2.8	25
46	Functional characterization of the <i>Mycobacterium tuberculosis</i> zinc metallopeptidase Zmp1 and identification of potential substrates. Biological Chemistry, 2012, 393, 631-640.	2.5	24
47	Cysteine proteinases produced by cultured rabbit V2 carcinoma cells and rabbit skin fibroblasts. International Journal of Cancer, 1986, 38, 753-761.	5.1	23
48	Cephem Sulfones as Inactivators of Human Leukocyte Elastase. 5. 7.alphaMethoxy- and 7.alphaChloro-1,1-dioxocephem 4-Ketones. Journal of Medicinal Chemistry, 1994, 37, 4003-4019.	6.4	23
49	Kinetics of Enzyme-Modifier Interactions. , 2015, , .		22
50	Purification and enzymological characterization of murine neurotrypsin. Protein Expression and Purification, 2008, 61, 13-21.	1.3	20
51	Probing the Activity Modification Space of the Cysteine Peptidase Cathepsin K with Novel Allosteric Modifiers. PLoS ONE, 2014, 9, e106642.	2.5	20
52	Folding Competence of N-terminally Truncated Forms of Human Procathepsin B. Journal of Biological Chemistry, 2005, 280, 11973-11980.	3.4	19
53	Co-oligopeptides containing two aromatic residues spaced by glycyl residues. 11. A conformational study of tryptophan- and glycine-containing oligopeptides based on the temperature dependence of proton NMR spectra. Journal of the American Chemical Society, 1979, 101, 5170-5178.	13.7	18
54	Co-oligopeptides containing two aromatic residues spaced by glycyl residues. X. Proton magnetic resonance study of co-oligopeptides of tryptophan and glycine. Biopolymers, 1979, 18, 995-1008.	2.4	17

#	Article	IF	CITATIONS
55	Interaction of human leukocyte elastase with soluble and insoluble protein substrates. A practical kinetic approach. BBA - Proteins and Proteomics, 1990, 1040, 355-364.	2.1	17
56	Calmodulin Is a Nonessential Activator of Secretory Phospholipase A ₂ . Biochemistry, 2009, 48, 11319-11328.	2.5	17
57	pH-dependent hysteretic behaviour of human myeloblastin (leucocyte proteinase 3). Biochemical Journal, 1996, 317, 901-905.	3.7	16
58	Further investigations of the transient kinetics of alcohol oxidation catalysed by horse liver alcohol dehydrogenase. Journal of Molecular Biology, 1977, 114, 267-279.	4.2	15
59	Electrostatic Interactions between Human Leukocyte Elastase and Sulfated Glycosaminoglycans: Physiological Implications. Biological Chemistry, 1997, 378, 1481-9.	2.5	15
60	Parallel pathways in the folding of a short-term denatured scFv fragment of an antibody. Folding & Design, 1998, 3, 39-49.	4.5	15
61	Fluorescence Properties of Reduced Thionicotinamide - Adenine Dinucleotide and of Its Complex with Octopine Dehydrogenase. FEBS Journal, 1978, 83, 601-607.	0.2	14
62	Investigations on the Kinetic Mechanism of Octopine Dehydrogenase. 2. Location of the Rate-Limiting Step for Enzyme Turnover. FEBS Journal, 1975, 59, 185-191.	0.2	13
63	Cleavage of human IgM with human lysosomal elastase. Immunology Letters, 1980, 2, 47-51.	2.5	13
64	Differential expression of mRNAs for endopeptidases in phenotypically modulated ('dedifferentiated') human articular chondrocytes. FEBS Letters, 1997, 412, 453-455.	2.8	13
65	Simultaneous interaction of enzymes with two modifiers: Reappraisal of kinetic models and new paradigms. Journal of Theoretical Biology, 2009, 261, 318-329.	1.7	13
66	Clusterin is a specific stabilizer and liberator of extracellular cathepsin K. FEBS Letters, 2012, 586, 1062-1066.	2.8	13
67	Dendrochronological investigation of the bowed string instruments at the Theatre Museum Carlo Schmidl in Trieste, Italy. Journal of Cultural Heritage, 2017, 27, S55-S62.	3.3	13
68	Interaction of the human leukocyte proteinases elastase and cathepsin G with gold, silver and copper compounds. Biochemical Pharmacology, 1984, 33, 1859-1865.	4.4	11
69	Zymogen activation of neurotrypsin and neurotrypsin-dependent agrin cleavage on the cell surface are enhanced by glycosaminoglycans. Biochemical Journal, 2013, 453, 83-100.	3.7	11
70	Paradoxical interactions between modifiers and elastaseâ€2. FEBS Journal, 2010, 277, 2486-2495.	4.7	10
71	Stopped-flow studies of the aerobic reduction of ascorbic acid oxidase. Journal of Molecular Catalysis, 1979, 6, 135-143.	1.2	9
72	Hysteretic Enzyme Response Induced by Inhibitory Antibodies against Human Leukocyte Elastase. Biological Chemistry Hoppe-Seyler, 1986, 367, 245-258.	1.4	6

#	Article	IF	Citations
73	Human Myeloblastin (Leukocyte Proteinase 3): Reactions with Substrates, Inactivators and Activators in Comparison with Leukocyte Elastase. Biological Chemistry Hoppe-Seyler, 1996, 377, 579-586.	1.4	6
74	Detection of a very rapid first phase in complex formation of DnaK and peptide substrate. FEBS Letters, 2002, 520, 25-29.	2.8	5
75	interferENZY: A Web-Based Tool for Enzymatic Assay Validation and Standardized Kinetic Analysis. Journal of Molecular Biology, 2021, 433, 166613.	4.2	4
76	Kinetics of the Interaction of Peptidases with Substrates and Modifiers. , 2013, , 37-84.		4
77	Basic Knowledge. , 2015, , 1-64.		3
78	Methodologic Problems Encountered in the Assay of Proteinases in Lewis Lung Carcinoma, a Mouse Metastasizing Tumor. Tumori, 1982, 68, 381-387.	1.1	2
79	The Basic Mechanisms of Inhibition and Nonessential Activation. , 2015, , 209-293.		1
80	Taxonomy of Enzyme–Modifier Interactions and the Specific Velocity Plot. , 2015, , 127-169.		1
81	Slow-Onset Enzyme Inhibition. , 2015, , 367-444.		1